Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Sitravatinib Maintenance in ES-SCLC
NCT05228496Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Mar 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sitravatinib in small cell lung cancer (SCLC), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
sitravatinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05228496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05228496.